Japan Chemical Daily

Japan's leading chemical industry newspaper

Log In

Daiichi Sankyo Sees Pillar of Growth in Next-Gen Biopharmaceuticals

Filed Under: Industry, Pharma Tagged With: , , , , , , , ,

Daiichi Sankyo Co. Ltd. (TYO:4568) is making antibody drug conjugates (ADCs) and other next-generation biopharmaceuticals a pillar for medium- and…...

Please subscribe to read the full story.

Subscribe Free Trial

Related Articles:

AGC in Race to Bolster CDMO Operations Across US, Europe and Japan
AGC in Race to Bolster CDMO Operations Across US, Europe and…
Spate of Japanese-Developed COVID-19 Vaccines Head Into Later Stages of Development, Clinical Trials
Spate of Japanese-Developed COVID-19 Vaccines Head Into…
Japan’s Leading Drug Manufacturers Grow Sales Revenue on Back of Mainstay Products
Japan’s Leading Drug Manufacturers Grow Sales Revenue on…
AGC Looks to Advance Into Gene and Cell Therapy Business With Tender Offer for MolMed
AGC Looks to Advance Into Gene and Cell Therapy Business…
Chemical and Material Companies Hit Crossroad on Health Care Strategy
Chemical and Material Companies Hit Crossroad on Health Care…
NOF Moves to Boost Production of DDS Materials for Biopharmaceuticals
NOF Moves to Boost Production of DDS Materials for…